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Background: Radiation therapy is the most widely used treatment for cancer, but it causes the side effect of
mucositis due to intestinal damage. We examined the protective effect of genistein in tumor-bearing mice after
abdominal irradiation by evaluation of apoptosis and intestinal morphological changes.
Methods: Mouse colon cancer CT26 cells were subcutaneously injected at the flank of BALB/c mice to generate
tumors. The tumor-bearing mice were treated with abdominal radiation at 5 and 10 Gy, and with genistein at
200 mg/kg body weight per day for 1 d before radiation. The changes in intestinal histology were evaluated 12 h
and 3.5 d after irradiation. To assess the effect of the combination treatment on the cancer growth, the tumor
volume was determined at sacrifice before tumor overgrowth occurred.
Results: Genistein significantly decreased the number of apoptotic nuclei compared with that in the irradiation
group 12 h after 5 Gy irradiation. Evaluation of histological changes showed that genistein ameliorated intestinal
morphological changes such as decreased crypt survival, villus shortening, and increased length of the basal lamina
3.5 d after 10 Gy irradiation. Moreover, the genistein-treated group exhibited more Ki-67-positive proliferating cells
in the jejunum than the irradiated control group, and crypt depths were greater in the genistein-treated group
than in the irradiated control group. The mean weight of the CT26 tumors was reduced in the group treated with
genistein and radiation compared with the control group.
Conclusion: Genistein had a protective effect on intestinal damage induced by irradiation and delayed tumor
growth. These results suggest that genistein is a useful candidate for preventing radiotherapy-induced intestinal
damage in cancer patients.Background
Radiation therapy plays an important role in the man-
agement of cancer. When radiation therapy is directed
towards pelvic and abdominal tumors, the malignancy is
often successfully controlled or eliminated. The gastro-
intestinal system often shows clinically relevant lesions
induced by physical factors such as ionizing radiation,
which is typically used in cancer therapy. Accompanying
injury to the surrounding intestinal tissue may result in
serious morbidity and occasional mortality. This so-
called radiation enterocolitis is a major clinical problem
because it is relatively unresponsive to usual therapies
and because of the intractable problems it may cause to* Correspondence: jskim@dirams.re.kr
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reproduction in any medium, provided the orthe patient [1,2]. Cancer patients undergoing radiother-
apy have suffered from adverse effects related to the for-
mation of free radicals, which cause oxidative damage to
normal cells, including intestinal crypt cells [3]. The pro-
tective effects of many compounds against radiation-
induced intestinal injuries have been investigated [4-7].
The side effects of irradiation may lead to reduced qual-
ity of life and can be dose-limiting, leading to treatment
reduction for the patient. Hence, if radioprotective
agents are combined with radiotherapy, it may be pos-
sible to differentially protect normal cells and kill the
cancer cells [4]. The focus of irradiation protection has
shifted to investigating the radioprotective potential of
natural products, including plants and herbs, in the hope
that suitable pharmacological agents, which protect
humans against the deleterious effects of ionizing. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fied [4].
Genistein, a multifunctional soy isoflavone, is a phyto-
chemical that occurs naturally in various plant-derived
foods. Genistein scavenges oxygen-derived free radicals
and possesses the capacity to activate antioxidant sys-
tems; this results in the reduction of free radical lipid
peroxidation products and stabilization of cell mem-
brane structure [8-10]. Thus, the antioxidant activity of
genistein may protect against radiation-induced cellular
damage in cancer patients. Previous studies on the
radio-protective effects of genistein in radiation-induced
myelosuppressed mice demonstrated that genistein can
increase the survival rate of irradiated mice [11-13]. Re-
cently, genistein has been shown to have a radioprotec-
tive effect in non-hematopoietic tissues, including the
lung and testis [8,14,15]. However, little is known about
the protective effect of genistein against radiation-
induced intestinal injury.
Genistein also inhibits the growth of cancer cells
through the modulation of genes related to the homeo-
static control of the cell cycle [16,17]. Understanding the
mechanisms involved in the radiosensitization effect of
genistein will reveal how it acts as a radiosensitizer in
various cancers [15,18-20]. A recent pre-clinical animal
study demonstrated enhanced lung tumor eradication
and normal lung protection by isoflavones [15]. In this
study, we examined the protective effect of genistein on
intestinal mucosal damage and the effect of genistein on
tumor radiation sensitivity in cancer-bearing mice.Methods
Animals and experimental procedures
Female BALB/c mice (6 weeks old) were purchased from
the Central Lab. Animal Inc., (Seoul, Korea) and used
after 1 week of quarantine and acclimatization. The ani-
mals were maintained in a room at 23°C ± 2°C, with a
relative humidity of 50% ± 5%, artificial lighting from
0800–2000 hours, and 13 ~ 18 air changes per hour.
They were provided a standard laboratory diet and water
ad libitum. All experimental procedures were carried
out in accordance with the NIH Guidelines for the Care
and Use of Laboratory Animals and were approved by
the Institutional Animal Care and Use Committee of the
Dongnam Institute Radiological and Medical Sciences.
The animals were cared for in accordance with the dic-
tates of the National Animal Welfare Law of Korea.
The BALB/c mouse CT26 colon cancer cell line
(Korean Cell Line Bank, Seoul, Korea) was cultured in
RPMI medium containing 10% fetal calf serum and 1%
antibiotics (penicillin, gentamicin and streptomycin;
Gibco BRL, Life Technologies Pty. Ltd., Victoria,
Australia). CT26 cells (1 × 107 cells per animal in 100 μlPBS) were injected subcutaneously into the flanks of
BALB/c mice.
After 7 d of xenograft implantation, when the tumors
had reached ~5 mm in diameter, the mice were randomly
divided into 6 groups as follows: (1) vehicle + sham irradi-
ation group (n = 15), (2) genistein + sham irradiation group
(n = 15), (3) vehicle + 5 Gy irradiation group (n = 15), (4)
genistein + 5 Gy irradiation (n = 15), (5) vehicle + 10 Gy
irradiation (n = 15), and (6) genistein + 10 Gy irradiation
(n = 15), according to the treatment schedule (Figure 1A).
The five mice were euthanized randomly in each group
12 h after irradiation, mice tumors were weighed and eval-
uated the intestinal apoptotic change. For histopathological
examination, the five mice were euthanized in each group
3.5 d after irradiation, mice tumors were weighed and eva-
luated intestine histological change. After 7 d after irradi-
ation, mice were euthanized in each group and mice
tumors were weighed.
Genistein and polyethylene glycol of molecular weight
400 (PEG) were obtained from Sigma Chemical Company
(St Louis, MO). Genistein was dissolved in PEG on the
day of the experiment by sonication for 20 sec (Heat
Systems-Ultrasonics Inc., Plainview, NY, USA). Genistein
was administered into the dorsal subcutaneous space at a
dose of 200 mg/kg body weight at 24 h prior to irra-
diation; the dose and dosage were considered opti-
mum for radioprotection, as reported previously [11,13]
(Figure 1A).
The anesthetized mice were positioned on a tray, and
the intestine and cancer lesion were confirmed to be in
the radiation field. The mice were imaged by in vivo
X-ray micro-computed tomography (NFR Polaris-G90,
Nanofocusray, Jeonju, Korea) before radiation exposure
as the pretreatment control. The mice received abdom-
inal body irradiation at 5 and 10 Gy doses using 6 MV
high-energy photon rays (ELEKTA, Stockholm, Sweden)
at a dose rate of 3.8 Gy/min for the evaluation of intes-
tinal injury and cancer changes. Sham-irradiated mice
were treated in exactly the same manner as the irra-
diated mice but without irradiation (Figure 1B).
Apoptosis assay
The mice (5 mice in each group) were euthanized 12 h
after irradiation (5 and 10 Gy), based on a report show-
ing that the maximum frequency of apoptotic cells was
observed after irradiation [21]. Small intestines were
fixed in 10% buffered formalin and embedded in
paraplast wax. Sections (4-μm thick) were cut and
stained using the TdT-mediated dUTP-biotin nick end
labeling (TUNEL) technique with a commercial kit
(ApopTag Plus Peroxidase In Situ Apoptosis Detection
kit, Intergen Co., Burlington, MA, USA). Apoptotic cells
were counted in the longitudinal crypt sections showing
a large portion of cells in the crypt base and lumen and
Figure 1 Reduction of radiation-induced intestinal injury in tumor-bearing mice by genistein: treatment schedule. (A) The mouse CT26
colon cancer cells were injected subcutaneously into the flanks of BALB/c mice. After 7 d of xenograft implantation, when the tumors had
reached ~ 5 mm in diameter, the mice were randomly divided into 6 groups and abdominal site exposed to 5 or 10 Gy irradiation in mice. The
mice were euthanized 12 h after irradiation, mice tumors were weighed and evaluated the intestinal apoptotic change. For histopathological
examination, the mice were euthanized in each group 3.5 day after irradiation, mice tumors were weighed and evaluated intestinal histological
change. After 7 d irradiation exposure, mice were euthanized in each group and mice tumors were weighed. (B) Abdominal site exposed to
irradiation in mice. Arrow is the cancer xenograft lesion.
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microscope. The cells were recorded as single cells
based on their size and clustering when several apop-
totic fragments were believed to represent the remains
of a single cell. Forty crypt sections were recorded for
each mouse [5,6].
Jejunal crypt assay and morphological changes
The mice (5 mice in each group) were euthanized 3.5 d
after gamma irradiation (5 and 10 Gy). The small intes-
tines were fixed in 10% buffered formalin and embedded
in paraplast wax to prepare 4-μm thick tissue sections of
jejunum for hematoxylin-eosin staining. Two sections
from 4 different parts of the jejunum from each animal
were prepared for histological examination. The regene-
rating crypts and villi in the jejunal cross-section were
then counted. To analyze morphological changes, all sam-
ples were sectioned and reoriented in successive slices to
identify those containing the longest villi. This technique
was used because it yielded more homogenous resultsthan those of standard techniques based merely on the
measurement of the 10 longest villi in a single slice per
sample. The length of the 10 longest villi, crypts, and basal
lamina of 10 enterocytes in each sample were measured.
Ten measurements were obtained per animal, for a total
of 50 measurements per group [5,7]. Images of intestinal
sections were obtained using a digital camera mounted on
a microscope (Leica DM IRBE, Leica Micro Systems
GmbH, Wetzlar, Germany). Quantification was performed
using image analysis software (Leica QWin, Leica
Microsystems, Wetzlar, Germany).
To assess cell proliferation in tissue samples, the prolifer-
ation antigen Ki-67 was analyzed by immunocytochemistry
using a polyclonal rabbit anti-Ki-67 antibody (Acris Anti-
bodies GmbH, Hiddenhausen, Germany; diluted 1:500).
Bound antibodies were detected with avidin-biotin peroxid-
ase (Elite kit, Vector, Burlingame, CA, USA), and the pero-
xidase reaction was developed using a diaminobenzidine
substrate kit (Vector). As controls, the primary antibody
was omitted from a few test sections in each experiment.
Figure 2 Photomicrographs of the apoptotic changes in the
jejunal crypts revealed by TUNEL assay 12 h after 5 Gy gamma
irradiation. (A) Sham control, (B) irradiation control, and (C)
genistein treatment prior to irradiation. (A) A small number of crypt
cells exhibited apoptosis in the sham control mice. (B) Irradiation
increased the expression of apoptotic nuclei in the crypt cells of the
jejunum. (C) The number of apoptotic cells decreased slightly in the
group treated with genistein compared with the irradiation control
group (A, B, and C). (D) Bar graphs showing the number of
apoptotic cells per crypt in the jejunum sections, as determined by
the TUNEL method, in the sham control group, irradiation control
group, and genistein-pretreated group exposed to 5 Gy irradiation.
The data are shown as the means ± SEM for 5 mice in each group.
*P < 0.05 as compared with the irradiation control group.
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being mounted.
Effect of genistein in combination with radiotherapy on
colon cancer in tumor-bearing mice
Tumor overgrowth occurred 14 d after injection of can-
cer cells (7 d after irradiation). To monitor tumor size of
mice, tumors were excised and weighed at different time
points 12 h, 3.5 d, and 7 d after irradiation exposure.
Statistical analysis
The data are reported as the means ± SEM. The data
were analyzed by one-way analysis of variance (ANOVA)
followed by a Student–Newman–Keuls post hoc test for
multiple comparisons. In all cases, a P value of <0.05
was considered significant.
Results
Anti-apoptotic effect of genistein in the jejunal crypts
The number of apoptotic cells in the jejunal crypts was
determined by the TUNEL method. Apoptosis was easily
recognized by TUNEL staining of entire apoptotic bo-
dies. Most of the apoptotic cells were observed in the
putative stem cell zone located at the bottom (base) of
the jejunal crypts (Figure 2). Only a small number of
crypt cells exhibited apoptosis in the sham-irradiated
mice (Figure 2A and D). Irradiation increased the ex-
pression of apoptotic nuclei in the jejunal crypts in a
dose-dependent manner (5 and 10 Gy), as demonstrated
by the TUNEL method (Figure 2B and D). The number
of apoptotic cells decreased significantly in the genistein-
treated group compared with the vehicle-treated 5 Gy
irradiated group (Figure 2C and D) (P < 0.05 vs. irradiation
group at 12 hours after 5 Gy). Although the adminis-
tration of genistein decreased the average number of
apoptotic cells in the crypts in 10 Gy irradiated group,
there was no significant difference between the vehicle-
and genistein-treated groups exposed to 10 Gy irradiation
(Figure 2D).
Protective effect of genistein on intestinal morphological
changes
Table 1 summarizes the morphological changes observed
in jejunal mucosa 3.5 d after 10 Gy irradiation. The mor-
phological changes observed in mouse jejunum are
shown in Figure 3. No significant changes in intestinal
morphology were seen in the 5 Gy irradiated mice as
compared with the sham group (data not shown). Tissue
sections of intestine from the sham group and the
genistein-treated non-irradiated group showed normal
morphology (Figure 3A–D, Table 1).
The number of surviving crypts in the irradiation group
decreased significantly 3.5 d after 10 Gy irradiation
(Figure 3E and F, Table 1). The number of surviving cryptsincreased significantly in the genistein-treated group
(Figure 3I and J, Table 1) compared with the irradiation
group (P < 0.01 vs. irradiation group 3.5 d after 10 Gy
irradiation). These results indicate that genistein pretreat-
ment significantly improved the survival of jejunal crypts in
irradiated mice.
The height and number of villi decreased significantly
in mice 3.5 d after 10 Gy irradiation compared with the
sham control group, demonstrating the injurious effects
of irradiation on the jejunal mucosa (Figure 3E and F).
The villus height was higher in the genistein-pretreated
groups (Figure 3J) than in the irradiation group with
vehicle treatment (Table 1; P < 0.05 vs. irradiation group
3.5 d after 10 Gy irradiation). Although a higher number
of villi was observed in the genistein-treated group
(Figure 3I, Table 1) than in the irradiation control group
Table 1 Effect of genistein treatment on histologic changes in the mouse small intestine 3.5 d after 10 Gy irradiation
Sham Genistein IR (10 Gy) Genistein + IR (10 Gy)
Number of crypts/circumstance 120.7 ± 2.5 109.1 ± 8.2 14.6 ± 2.5 24.6 ± 2.6*
Number of villi/circumstance 40.6 ± 2.7 41.1 ± 3.8 32.6 ± 1.8 35.5 ± 1.7
Villus height (μm) 398.6 ± 13.8 378.4 ± 18.1 124.0 ± 7.2 186.2 ± 12.5**
Crypt depth (μm) 89.6 ± 5.8 90.1 ± 4.8 98.9 ± 4.2 136.8 ± 7.1**
Basal lamina length (μm/10 enterocytes) 44.6 ± 3.0 41.4 ± 6.2 123.1 ± 10.4 95.7 ± 5.9*
Data are shown as means ± SEM (*P < 0.05, **P < 0.01 vs. IR control group).
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difference.
The crypt depths were greater in the mice that re-
ceived irradiation, reflecting the intestinal response that
follows injury and leads to repair (Figure 3G, Table 1).
However, the crypt depths were increased in the
genistein-treated group compared with the irradiation
group (Figure 3K, Table 1; P < 0.05 vs. irradiation group
3.5 d after 10 Gy).
Comparison of the lengths of basal lamina per 10
enterocytes in the mouse jejunum is shown in Figure 3D,
H, and L. The lengths of the basal lamina of enterocytes
were increased in the irradiation groups compared toFigure 3 Photomicrographs showing crypt survival (A, E, and I), villus
basal lamina of 10 enterocytes (D, H, and L) in the jejunal circumferen
control group, (E–H) irradiation control group, and (I–L) genistein-pretreate
group show normal morphology. The genistein-pretreated group exposed
crypt depth when compared with the irradiation control group exposed to
genistein-pretreated group (I) exhibited a shorter basal lamina length when
magnification × 40; (B, F, and J) magnification × 100; (C, G, and K) magnificthe control group. However, the genistein-pretreated
group exhibited shorter enterocyte basal lamina than
that of the irradiation group, indicative of reduced injury
in the genistein-pretreated group (Table 1; P < 0.05 vs.
irradiation group 3.5 d after 10 Gy).
Proliferating cells were identified by immunohisto-
chemical staining of Ki-67 [7,22] (Figure 4). Most Ki-
67-positive cells were detected in the jejunal crypts.
The number of Ki-67-positive cells decreased in
irradiated mice, corresponding to the decrease in sur-
viving crypts 3.5 d after 10 Gy irradiation. A greater
number of Ki-67-positive cells was observed in the
genistein-pretreated group compared with the irradiationheight (B, F, and J), crypt depth (C, G, and K), and lengths of the
ce, as revealed by hematoxylin and eosin staining. (A–D) Sham
d group 3.5 d after 10 Gy irradiation. Intestinal sections from the sham
to 10 Gy irradiation exhibited increased crypt survival, villi length, and
10 Gy irradiation at this magnification and in cross section. The
compared with the 10 Gy irradiation control group (H). (A, E, and I)
ation × 200; (D, H and L) magnification × 400.
Figure 4 Photomicrographs of progenitor cells in the jejunum circumference stained with an antibody for Ki-67. (A and B) Sham control
group, (C and D) irradiation control group, and (E and F) genistein-pretreatment group 3.5 d after 10 Gy irradiation. Most of the Ki-67-positive
cells were detected in the jejunal crypts. The number of Ki-67-positive cells decreased in irradiated mice, which corresponded to surviving crypts
at 3.5 d after 10 Gy irradiation. However, higher Ki-67 expression was observed in crypts of increased depth in irradiated groups compared with
the sham control group. A greater number of Ki-67-positive cells was observed in the genistein-treated group than in the irradiation control
group at this magnification. (A, C, and E) magnification × 100. (B, D, and F) magnification × 400.
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(Figure 4). The difference in Ki-67 expression between
the irradiation group and the genistein-pretreated group
indicates the better survival of crypts in the genistein-
pretreated group.
Effect of genistein on sensitivity to radiation in CT26 cell
xenografted mice
After 12 hr, 3.5 and 7 d, mice (5 mice in each group) with
tumors were euthanized, and the tumors were weighed. Al-
though genistein alone and 5 Gy irradiation alone de-
creased the size of the tumors compared with the sham
group, the difference was not significant. Compared with
controls, 10 Gy irradiation alone and combination therapy
resulted in a significant decrease in tumor size after 7 dTable 2 Effect of genistein treatment on tumor weight in CT2
5 and 10 Gy irradiation
Sham Genistein IR (5 Gy)
Post IR 12 h 0.22 ± 0.05 0.2 ± 0.03 0.24 ± 0.04
Post IR 3.5 d 0.45 ± 0.08 0.42 ± 0.07 0.45 ± 0.09
Post IR 7 d 0.75 ± 0.06 0.66 ± 0.04 0.72 ± 0.06
The data are shown as means ± SEM for 5 mice in each group. (,*P < 0.05, vs. sham(P < 0.05 vs. sham group 7 d after 10 Gy). Combined treat-
ment (10 Gy + genistein) produced the best tumor regres-
sion and growth inhibition among the 6 groups, with no
significant difference between the vehicle and genistein
treated groups (Table 2; P = 0.5, 10 Gy group vs. 10 Gy +
genistein group).
Discussion
This study examined the levels of radiation-induced
damage to small intestinal cells to determine the pro-
tective effect of genistein. The results showed that genis-
tein has the ability to regulate progenitor cell survival
and cell death in the small intestine.
To evaluate radiation-induced intestinal damage, we de-
termined the number of villi and crypts, villus height,6 cell xenografted BALB/c mice 12 h, 3.5 and 7 day after
Genistein + IR (5 Gy) IR (10 Gy) Genistein + IR (10 Gy)
0.17 ± 0.04 0.18 ± 0.03 0.18 ± 0.04
0.44 ± 0.05 0.41 ± 0.03 0.39 ± 0.04
0.63 ± 0.06 0.58 ± 0.04* 0.53 ± 0.06*
group).
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after irradiation. The height of the villi and number of sur-
viving crypts may be very sensitive and suitable
biodosimetric markers after irradiation [6,7,23]. Cell pro-
liferation in the crypts retards the developing intestinal
damage, but after higher doses of radiation, the recovery
mechanism of cell repopulation is insufficient [24]. The
acute effects of irradiation on the intestinal mucosa are
generally ascribed to inhibition of mitosis in the crypts
[25]. This loss of proliferative function results in the devel-
opment of epithelium and renders the intestine permeable
to luminal bacteria and antigens, which may exacerbate
mucosal inflammation and dysfunction or cause
bacteremia [2]. The expression of Ki-67, a proliferative
marker in the jejunum, increased in the genistein-treated
group; this may indicate the recovery of intestinal damage
after irradiation. Thus, genistein can attenuate various
morphological changes due to intestinal injury after irradi-
ation. These results demonstrate that genistein provides
significant protection against intestinal injury following ir-
radiation. Although clinical radiotherapy usually involves
fractioned radiation doses and not a single therapy, this
study aimed to identify the radioprotective effect of genis-
tein on intestinal injury induced by radiation rather than
its anti-cancer effect. Therefore we used a single dose of
radiation to induce intestinal injury because it is difficult
to induce intestinal injury by fractioned radiation. Com-
pared with fractioned radiation, the single exposure
resulted in considerably less intestinal injury, indicating a
substantial recovery during the 6 hr span between radi-
ation fractions [26].
Most irradiation damage in biological systems is
caused by the generation of reactive oxygen species.
Various mechanisms, including the prevention of dam-
age through inhibition of free radical generation or their
intensified scavenging, enhancement of DNA and mem-
brane repair, replenishment of dead hematopoietic and
other cells, and stimulation of immune cell activity, are
considered important for radioprotection [4]. The
antioxidative properties of genistein, combined with its
capacity to activate antioxidant systems, reduce lipid
peroxidation and stabilize cell membrane structure
[9,10]. Arora et al. found that soy isoflavones can hinder
the diffusion of free radicals and thereby decrease the
kinetics of free radical reactions, which might help to
stabilize cell membrane structure [27]. In our previous
study, we showed that genistein can significantly de-
crease the level of radiation-induced reactive oxygen
species in the testis, suggesting that genistein protects
against radiation-induced testicular injury via a protect-
ive mechanism that includes antioxidative activity [8].
Thus, the antioxidant activity of genistein, i.e., its ability
to protect against irradiation-induced cytogenetic dam-
age, may contribute to its radioprotective action.Moreover, genistein binds to the estrogen receptor due
to its biphenolic structure and may mimic or modulate
the actions of endogenous estrogens [28]. These include
its estrogenic activity and its role in signal transduction
pathways where it is an inhibitor of topoisomerase, pro-
tein kinases, and caspases involved in apoptotic path-
ways [16,29]. Anti-apoptotic effects have been reported
to be associated with protection after radiation-induced
intestinal injury [5-7]. Furthermore, estrogen has been
shown to protect the gut in a model of inflammatory
bowel disease, and this effect is mediated via the estro-
gen receptor [30]. Another study indicated that estrogen
also attenuates intestinal injury following trauma-
hemorrhage via upregulation of the Akt pathway [31].
Although further studies are required to better under-
stand the protective effects of genistein, estrogen may
contribute to the anti-inflammatory effect of genistein
along with anti-apoptotic pathways and the Akt
pathway.
Genistein administration stimulated serum granulocyte-
colony stimulating factor (G-CSF) after sham irradiation
or gamma-irradiation [32]. Recent study showed the
radioprotective effect of some agents is mediated the
through G-CSF induction [33,34]. Further previous our
study also showed that G-CSF attenuated intestinal dam-
age after radiation exposure [7]. G-CSF activates several
signaling pathways to promote survival and proliferation,
and it also protects against apoptosis after irradiation
exposure [7,35,36]. The induction of G-CSF by genistein
is also responsible for protection against radiation injury.
Furthermore, genistein has gained increasing attention
because of its association with beneficial effects in cancer
chemoprevention [15,18,19,37,38]. This study showed that
a single treatment of genistein alone does not decrease tu-
mors compared with the sham group, no significant differ-
ence was observed between treatment with vehicle and
genistein with radiation exposure. Although, the single
treatment of genistein has not effects on the cancer cell in
this study, other studies have demonstrated that continu-
ously treatment of genistein shows additive benefits in
tumor radiotherapy, resulting in greater therapeutic effi-
cacy [18,19]. This study showed that combination therapy
with 10 Gy irradiation and genistein produced the best
tumor regression and growth inhibition among the
groups. The results showed that combination therapy with
10 Gy irradiation and genistein produced the best tumor
regression and growth inhibition among the groups. Some
reports have shown that genistein used alone in vivo as
well as in vitro can delay the growth of tumors [37,38].
Some authors indicated that genistein in combination
with other agents can delay tumor growth by inhibiting
angiogenesis [39]. Hillman et al. [18,19] also showed that
genistein combined with irradiation for prostate cancer
and renal cancer led to improved control of primary
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with genistein or irradiation alone [18-20]. Further, a re-
cent study showed that soy isoflavones augment the de-
struction of lung cancer by radiation and also mitigate
vascular damage, inflammation, and lung fibrosis caused
by radiation injury to normal lung tissue [15].
Although the cancer patients might benefit from
radiotherapy, it is not devoid of side effects. Among pa-
tients receiving abdominal radiotherpay more than 70%
develop gastro intestinal symptoms during treatment
[40]. Our findings show that genistein reduces various
parameters related to intestinal injury caused by radi-
ation exposure, but has not an effect on the tumor
growth in cancer-bearing mice. Therefore, genistein may
be clinically useful for colon cancer patients who require
radiotherapy.
Conclusion
Genistein has a potential role in protection against
radiation-induced intestinal damage while providing
radiosensitizing effect on tumor cells. Genistein treat-
ment protected mice from apoptosis in the jejunal crypt
12 h after 5 Gy irradiation and restored various parame-
ters related to intestinal injury 3.5 d following 10 Gy
irradiation in tumor-bearing mice. The weight of cancers
was lesser in genistein- and irradiation-treated mice than
in mice receiving each single treatment. In conclusion,
genistein is a candidate drug that may protect intestinal
cells from the side effects of radiation therapy and pro-
vide a radiosensitizing effect on tumor cells.
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